Trial Profile

Phase III trial of telatinib in combination with a standard chemotherapy regimen for advanced gastric cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 16 Jun 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telatinib (Primary) ; Antineoplastics
Indications Gastric cancer
Focus Registrational; Therapeutic Use

Most Recent Events

02 Jun 2011 The FDA has approved the design of this trial under a Special Protocol Assessment.
28 Feb 2011 ACT Biotech has filed a Special Protocol Assessment (SPA) with the US FDA for this trial, according to an ACT Biotech media release.
13 Oct 2010 ACT Biotech is on track to file for marketing approval in the USA and Europe in 2014, according to a ACT Biotech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com